| Similar Articles |
|---|
 |
The Motley Fool
November 11, 2009
Robert Steyer |
There Will Be Blood (Plasma) Talecris Biotherapeutics Holdings introduces itself to investors with a bloody good third quarter.   |
The Motley Fool
December 3, 2009
Brian Orelli |
I Love This Industry With double-digit gains, how could you not love the biotech industry? |
The Motley Fool
August 9, 2010
Brian Orelli |
Dendreon's in Trouble Provided you call a slap on the wrist from the FDA "trouble." |
The Motley Fool
May 26, 2009
Brian Orelli |
Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected. |
The Motley Fool
March 13, 2009
Brian Orelli |
Will These Drugs Get Past the FDA? Let's take a look at which pharma companies are hoping to score with the FDA this month. |
The Motley Fool
October 2, 2009
Brian Orelli |
A Plasma-tastic IPO Talecris Biotherapeutics debuted on the public markets yesterday, raising $950 million for the company. That's the second largest IPO of the year so far. |
The Motley Fool
January 12, 2010
Brian Orelli |
Swine Flu: The Side Dish That Couldn't Last More governments canceling vaccine-purchasing contracts. The sky is falling on swine-flu-vaccine makers. |
The Motley Fool
March 27, 2009
Brian Orelli |
Dyax: A Cinderella Story Ends in a Fall FDA asks Dyax for more information. |
